Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: A 24-month follow-up of 68 patients

Moretti, Rita; Torre, Paola; Antonello, Rodolfo M.; Cazzato, Giuseppe; Griggio, Stefania; Bava, Antonio

doi:10.1177/153331750301800410

Cited by 95 publications

(51 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pharmacological interventions used for FTD are based on neurotransmitter replacement strategies. Anecdotal reports and a number of small, and uncontrolled studies have shown that treatment with antidepressants (Chow and Mendez, 2002) or atypical antipsychotics (Moretti et al, 2003b) can be associated with improvement of behavioral symptoms. Moretti et al (2004) showed a decrease of behavioral disturbance by rivastigmine, demonstrated by a significant reduction of the NPI total score between baseline and final visit after 12 months.…”

Section: Discussionmentioning

confidence: 99%

A 6‐month, open‐label study of memantine in patients with frontotemporal dementia

Diehl‐Schmid

Förstl

Perneczky

et al. 2008

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A 6‐month, open‐label study of memantine in patients with frontotemporal dementia

Diehl‐Schmid

Förstl

Perneczky

et al. 2008

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…59 The mechanism with which these medications reduce agitation is not fully understood. A case report 60 with risperidone and an open-label uncontrolled study 61 of olanzapine support the use of these medications in FTD. The reduction in the NPI observed with olanzapine treatment was similar in magnitude to that observed with antidepressant treatment (see table E-2).…”

Section: Treatment Reviewmentioning

confidence: 99%

A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia

2006

View full text Add to dashboard Cite

Objective-To evaluate neurotransmitter deficiencies and neurotransmitter-based treatments for frontotemporal dementia (FTD).Methods-The authors conducted a systematic review of the literature on the mechanism and treatment of FTD and a meta-analysis of treatment studies of antidepressants for the behavioral symptoms of FTD.Results-Patients with FTD show deficiencies in the serotonin and dopamine neurotransmitter systems, while the acetylcholine system appears relatively intact. Antidepressant treatment significantly improves behavioral symptoms in FTD, but most studies are small and uncontrolled. Serotonergic treatments appear to improve the behavioral but not cognitive symptoms of FTD.Conclusions-Studies of neurotransmitter deficiencies in frontotemporal dementia (FTD) can be helpful in developing treatments. Treatment studies on FTD are scarce, given the prevalence and severity of this illness. Larger, well-controlled treatment studies are required to reach more definitive conclusions about treatment efficacy. Multicenter studies are likely the best way to complete treatment studies in a timely manner.Frontotemporal dementia (FTD) is increasingly recognized as an important cause of dementia. 1 The symptoms of FTD include behavioral symptoms such as disinhibition, inappropriate social behavior, and apathy. Other symptoms include language and executive dysfunction. 2,3 The behavioral symptoms of FTD can be difficult to manage for caregivers and clinicians.The paucity of pharmacologic trials for FTD is likely due to the only recent clinical definition of the illness, limitations in understanding the biology of FTD, and the difficulty of assembling well-characterized groups of patients.

show abstract

“…The literature describes one case treated with risperidone 90 and an open trial with olanzapine that favours use of the drug. 91 Other dopaminergic agents, such as selegiline (IMAO-B), 92 have been used successfully to reduce neuropsychiatric symptoms. Methylphenidate has also been tested in patients with bvFTD with satisfactory results.…”

Section: Treatmentmentioning

confidence: 99%

Behavioural variant frontotemporal dementia: Clinical and therapeutic approaches

Fernández‐Matarrubia

Matías‐Guiu

Moreno‐Ramos

2014

Neurología (English Edition)

View full text Add to dashboard Cite

Introduction: Behavioural variant frontotemporal dementia (bvFTD) is the most frequent presentation in the clinical spectrum of frontotemporal dementia (FTD) and it is characterised by progressive changes in personality and conduct. Major breakthroughs in molecular biology and genetics made during the last two decades have lent us a better understanding of this syndrome, which may be the first manifestation in many different neurodegenerative diseases. Development:We reviewed the main epidemiological, clinical, diagnostic and therapeutic aspects of bvFTD. Most cases manifest sporadically and the average age of onset is 58 years. Current criteria for bvFTD propose three levels of diagnostic certainty: possible, probable, and definite. Clinical diagnosis is based on a detailed medical history provided by family members and caregivers, in conjunction with neuropsychological testing. Treatments which have been used in bvFDT to date are all symptomatic and their effectiveness is debatable. New drugs designed for specific molecular targets that are implicated in frontotemporal lobar degeneration are being developed.Conclusions: BvFDT is a frequent cause of dementia. It is a non-specific syndrome associated with heterogeneous histopathological and biomolecular findings. The definition of clinical subtypes complemented by biomarker identification may help predict the underlying pathology. This knowledge, along with the development of drugs designed for molecular targets, will offer new treatment possibilities. Demencia frontotemporal variante conductual; Degeneración lobar frontotemporal; Clínica; Diagnóstico; Criterios diagnósticos; Tratamiento Demencia frontotemporal variante conductual: aproximación clínica y terapéutica Resumen Introducción: La variante conductual de la demencia frontotemporal (DFT vc) es el síndrome clínico más frecuente de las demencias frontotemporales (DFT) y se caracteriza por una alteración progresiva de la personalidad y la conducta. En las últimas 2 décadas, los avances en biología molecular y genética han contribuido a un mayor conocimiento de esta entidad, que puede ser el modo de presentación de diferentes enfermedades neurodegenerativas.Desarrollo: Se revisan los principales aspectos epidemiológicos, clínicos, diagnósticos y terapéuticos de la DFT vc. La mayoría de los casos son esporádicos, iniciándose en torno a los 58 años de media. Los criterios diagnósticos vigentes establecen 3 niveles de certeza diagnós-tica: posible, probable y definitivo. El diagnóstico clínico se basa en la anamnesis detallada de familiares, complementada con la realización de test neuropsicológicos dirigidos. Hasta la fecha, los tratamientos empleados son solo sintomáticos y de eficacia controvertida. Se están diseñando fármacos dirigidos contra dianas moleculares específicas implicadas en la patogenia de las degeneraciones lobares frontotemporales.Conclusiones: La DFT vc es una causa frecuente de demencia. Se trata de un síndrome amplio, heterogéneo desde el punto de vista histopatológico y biomolecular. La de...

show abstract

Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: A 24-month follow-up of 68 patients

Cited by 95 publications

References 26 publications

A 6‐month, open‐label study of memantine in patients with frontotemporal dementia

A 6‐month, open‐label study of memantine in patients with frontotemporal dementia

A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia

Behavioural variant frontotemporal dementia: Clinical and therapeutic approaches

Contact Info

Product

Resources

About